Cargando…
PB2100: MANAGEMENT OF RELAPSED / REFRACTORY (R/R) B-CELL NON HODGKIN LYMPHOMA (B-NHL) WITH ANTI-CD20XCD3 BISPECIFIC ANTIBODY GLOFITAMAB. A SINGLE CENTER EXPERIENCE.
Autores principales: | Giatra, C., Souravla, E., Darmani, I., Roumelioti, A., Kaouranis, K., Kosmas, P., Bampali, V., Gardeli, D., Papageorgiou, M., Mellios, Z., Karaolidou, F., Tsonis, I., Karatza, M., George, K., Marinos, L., Karakasis, D., Karmiris, T., Bakiri, M., Bouzani, M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429373/ http://dx.doi.org/10.1097/01.HS9.0000851232.61292.37 |
Ejemplares similares
-
PB2101: TREATMENT OF AGGRESSIVE B-CELL LYMPHOMA WITH DA-EPOCH-R, A SINGLE CENTRE EXPERIENCE
por: Dimitraki, E.-K., et al.
Publicado: (2022) -
PB2140: ALLOGENEIC STEM CELL TRANSPLANTATION IN RARE T-NHL SUBTYPES: FOCUS ON AITL, MF/SS, HSTCL. A SINGLE BMT-UNIT EXPERIENCE.
por: Tzenou, T., et al.
Publicado: (2022) -
P1179: PROGNOSIS OF PATIENTS WITH AGGRESSIVE REFRACTORY B-NHL TREATED WITH GLOFITAMAB IN REAL CLINICAL PRACTICE
por: Fedorova, Liudmila, et al.
Publicado: (2023) -
Glofitamab: First Approval
por: Shirley, Matt
Publicado: (2023) -
Glofitamab Treatment in Relapsed or Refractory DLBCL after CAR T-Cell Therapy
por: Rentsch, Vera, et al.
Publicado: (2022)